Half Year 2025 Biocon Ltd Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Harith Ahamed - Spark Capital - Analyst : So my first question is on the reported revenues of Biocon Biologics, which is around INR2,200 crores for the quarter and almost INR4,300 crores for the first half. Will you be able to give an indication of the breakup of these revenues between US, Europe and other markets?

Question: Harith Ahamed - Spark Capital - Analyst : Okay. And Kedar, if you can provide the R&D spend at Biocon Biologics for the quarter, I could find the R&D spend at the consolidated level. But just for Biocon Biologics, if you could share that, that would be helpful.

Question: Harith Ahamed - Spark Capital - Analyst : Okay. And last one from my side is on the net debt movement quarter on quarter. So in the first half, we received proceeds from Eris to the tune of around INR1,100 crores. But despite that, there is an increase in net debt at a consolidated level of around INR400 crores, I understand there's an outflow related to the deferred consideration to IFRS, but the number I'm seeing is around INR840 crores. So just trying to understand why there is such a high negative free cash flow during the first half. And in that context, how should we think about CapEx given net debt reduction is a priority, shouldn't we be looking at moderated CapEx spends, I see that number at around INR900 crores in the first half. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. OCTOBER 30, 2024 / 1:00PM, BION.NS - Half Year 2025 Biocon Ltd Earnings Call